Nitric oxide synthase activities in human myocardium.

Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest (1999) 2.94

Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest (2002) 1.70

The induction of nitric oxide synthase and intestinal vascular permeability by endotoxin in the rat. Br J Pharmacol (1993) 1.51

Nitric oxide regulates the calcium current in isolated human atrial myocytes. J Clin Invest (1995) 1.33

Cyclic GMP regulation of the L-type Ca(2+) channel current in human atrial myocytes. J Physiol (2001) 1.26

cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. J Clin Invest (1997) 1.23

Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management. Postgrad Med J (2001) 1.18

Nitric oxide and cardioprotection during ischemia-reperfusion. Heart Fail Rev (2002) 1.16

Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest (1994) 1.13

The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumour necrosis factor-alpha. Br J Pharmacol (1995) 1.12

Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences. Am J Physiol Heart Circ Physiol (2005) 1.09

The nitric oxide-endothelin-1 connection. Heart Fail Rev (2003) 1.06

The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. J Clin Invest (1995) 1.05

beta(3)-adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility. J Clin Invest (2000) 1.00

Biology and clinical relevance of nitric oxide. BMJ (1994) 0.97

Myocardial contractile effects of nitric oxide. Heart Fail Rev (2002) 0.88

Nitric oxide and myocardial function in heart failure: friend or foe? Heart (2002) 0.87

The role of nitric oxide in the failing heart. Heart Fail Rev (2001) 0.85

Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences. Basic Res Cardiol (2011) 0.84

Myocardial calcium-independent nitric oxide synthase activity is present in dilated cardiomyopathy, myocarditis, and postpartum cardiomyopathy but not in ischaemic or valvar heart disease. Br Heart J (1995) 0.83

Therapeutic inhibition of tumour necrosis factor alpha in patients with heart failure: cooling an inflamed heart. Heart (2003) 0.81

The role of nitric oxide in cardiac surgery. Surg Today (1997) 0.79

Foot-and-Mouth Disease Virus-Associated Abortion and Vertical Transmission following Acute Infection in Cattle under Natural Conditions. PLoS One (2016) 0.78

eNOS Gene Variant in Patients with Coronary Artery Disease. J Biomark (2012) 0.78

Subacute inflammatory activation in subjects with acute coronary syndrome and left ventricular dysfunction. Inflammation (2012) 0.78

Nitric oxide, cell death, and heart failure. Heart Fail Rev (2002) 0.78

Comparison of the ability of nicardipine, theophylline and zaprinast to restore cardiovascular haemodynamics following inhibition of nitric oxide synthesis. Br J Pharmacol (1994) 0.76

Inducible nitric oxide synthase in the cardiovascular system. Heart (1996) 0.76

Nitric oxide synthase activities in human myocardium. Lancet (1993) 0.75

Nitric oxide synthase activities in human myocardium. Lancet (1993) 0.75

Minocycline attenuates cirrhotic cardiomyopathy and portal hypertension in a rat model: Possible involvement of nitric oxide pathway. Iran J Basic Med Sci (2016) 0.75

Gross cholestatic dysfunction in giant cell arteritis. Postgrad Med J (1995) 0.75

Plasma nitrate plus nitrite changes during continuous intravenous infusion interleukin 2. Br J Cancer (1996) 0.75

Quenching the effects of L-arginine on free radical injury in cultured cardiomyocytes. Surg Today (1998) 0.75

Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44

Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 18.41

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19

Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature (1986) 9.93

Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol (1990) 8.85

Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A (1989) 8.34

Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc Natl Acad Sci U S A (1989) 7.79

L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun (1988) 7.77

Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 7.69

Nitric oxide synthases in mammals. Biochem J (1994) 6.50

A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol (1989) 6.30

Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins. Cell (1995) 6.24

Altered immune responses in mice lacking inducible nitric oxide synthase. Nature (1995) 6.20

Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol (1990) 5.87

Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol (1971) 5.62

Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (1992) 5.36

Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol (1987) 5.23

A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun (1989) 5.14

The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol (1987) 4.88

Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev (1978) 4.66

Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet (1987) 4.55

Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54

Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A (1990) 4.49

Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44

Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol (1986) 4.23

Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett (1994) 4.19

Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol (1988) 4.16

Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet (1977) 4.11

An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A (1990) 3.98

Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins (1977) 3.74

Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet (1978) 3.74

Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J (1989) 3.70

The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63

Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis. Development (1994) 3.53

Control of antibiotic biosynthesis. Microbiol Rev (1980) 3.44

Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med (1989) 3.44

Widespread tissue distribution, species distribution and changes in activity of Ca(2+)-dependent and Ca(2+)-independent nitric oxide synthases. FEBS Lett (1991) 3.43

Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med (1979) 3.29

Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A (1995) 3.28

Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res (1977) 3.28

The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun (1987) 3.25

Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature (1973) 3.20

Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res (1992) 3.15

Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun (1990) 3.14

Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci U S A (1998) 3.10

An improved method for washing of human platelets with prostacyclin. Thromb Res (1983) 3.07

Control of regional blood flow by endothelium-derived nitric oxide. Hypertension (1990) 2.93

Cholesterol modification of sonic hedgehog is required for long-range signaling activity and effective modulation of signaling by Ptc1. Cell (2001) 2.84

Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83

The influence of shared mental models on team process and performance. J Appl Psychol (2000) 2.80

Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun (1991) 2.79

Function of Rieger syndrome gene in left-right asymmetry and craniofacial development. Nature (1999) 2.78

Nitric oxide from L-arginine stimulates the soluble guanylate cyclase in adrenal glands. Biochem Biophys Res Commun (1989) 2.73

Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A (1994) 2.70

Nitric oxide synthesized from L-arginine regulates vascular tone in the coronary circulation of the rabbit. Br J Pharmacol (1989) 2.68

Detection of Coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet (1986) 2.68

Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins (1977) 2.67

Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis (1992) 2.63

Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis (1989) 2.58

King's endomyocardial bioptome. Lancet (1974) 2.55

NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol (1989) 2.53

Arrest of preterm labour and prolongation of gestation with glyceryl trinitrate, a nitric oxide donor. Lancet (1994) 2.53

Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull (1978) 2.51

Production of hydroxyl radicals from the simultaneous generation of superoxide and nitric oxide. Biochem J (1992) 2.51

Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins (1977) 2.48

Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet (1992) 2.44

Liquid crystal thermography as a screening test for deep-vein thrombosis. Lancet (1985) 2.40

Mutational analysis of the DNA binding, dimerization, and transcriptional activation domains of MEF2C. Mol Cell Biol (1996) 2.40

S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol (1992) 2.39

The role of TH1 and TH2 cells in a rodent malaria infection. Science (1993) 2.38

Modulation of acute inflammation by endogenous nitric oxide. Eur J Pharmacol (1992) 2.32

Acetylcholine induces vasodilatation in the rabbit isolated heart through the release of nitric oxide, the endogenous nitrovasodilator. Br J Pharmacol (1988) 2.32

Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun (1990) 2.31

Anti-inflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat. Biochem Biophys Res Commun (1990) 2.31

A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins (1976) 2.28

Nitric oxide synthase activity in human gynecological cancer. Cancer Res (1994) 2.27

Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol (1999) 2.26

Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature (1980) 2.24

Nitric oxide synthase activity in human breast cancer. Br J Cancer (1995) 2.22

Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet (1993) 2.20

Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia. Circulation (1995) 2.18

cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A (1996) 2.17

A possible novel pathway of regulation by murine T helper type-2 (Th2) cells of a Th1 cell activity via the modulation of the induction of nitric oxide synthase on macrophages. Eur J Immunol (1991) 2.15

Role of leukocytes in acute myocardial infarction in anesthetized dogs: relationship to myocardial salvage by anti-inflammatory drugs. J Pharmacol Exp Ther (1984) 2.12

Penicillin and cephalosporin biosynthetic genes: structure, organization, regulation, and evolution. Annu Rev Microbiol (1992) 2.10

Cloning, characterization, and expression of a cDNA encoding an inducible nitric oxide synthase from the human chondrocyte. Proc Natl Acad Sci U S A (1993) 2.10

Expression of mef2 genes in the mouse central nervous system suggests a role in neuronal maturation. J Neurosci (1995) 2.10

Induction and potential biological relevance of a Ca(2+)-independent nitric oxide synthase in the myocardium. Br J Pharmacol (1992) 2.09

Interleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-gamma in murine macrophages. Biochem Biophys Res Commun (1992) 2.08

Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs. Br J Pharmacol (1973) 2.07

The effects of prostagladin endoperoxides and thromboxane A2 on strips of rabbit coeliac artery and certain other smooth muscle preparations [proceedings]. Br J Pharmacol (1976) 2.06

Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet (1990) 2.04

Different responses of astrocytes and neurons to nitric oxide: the role of glycolytically generated ATP in astrocyte protection. Proc Natl Acad Sci U S A (2001) 2.03

Mechanism of action of some inhibitors of endothelium-derived relaxing factor. Proc Natl Acad Sci U S A (1986) 2.03

Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin. Br J Pharmacol (1982) 2.01

Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation (2000) 2.01

The effects of BW755C and other anti-inflammatory drugs on eicosanoid concentrations and leukocyte accumulation in experimentally-induced acute inflammation. J Pharm Pharmacol (1983) 2.00